drugset / Trial / NCT03805399
FUSCC Refractory TNBC Umbrella (FUTURE)
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase Ib/II, open-label, multi-center umbrella study evaluating the efficacy and safety of multiple targeted treatment in patients with refractory metastatic TNBC.The specific grouping of patients' depends on FUSCC 500+ gene panel testing and IHC subtype staining.
Timeline
- Start
- 2018-10-18
- Primary completion
- 2022-12-01
- Completion
- 2022-12-01
Publications
- Liu CC, Chen L, Cai YW, Chen YF, Liu YM, Zhou YJ, Shao ZM, Yu KD. Targeting EMSY-mediated methionine metabolism is a potential therapeutic strategy for triple-negative breast cancer. Cell Rep Med. 2024 Feb 20;5(2):101396. doi: 10.1016/j.xcrm.2024.101396. Epub 2024 Jan 29.
- Xiao Y, Ma D, Yang YS, Yang F, Ding JH, Gong Y, Jiang L, Ge LP, Wu SY, Yu Q, Zhang Q, Bertucci F, Sun Q, Hu X, Li DQ, Shao ZM, Jiang YZ. Comprehensive metabolomics expands precision medicine for triple-negative breast cancer. Cell Res. 2022 May;32(5):477-490. doi: 10.1038/s41422-022-00614-0. Epub 2022 Feb 1.
- Jiang YZ, Liu Y, Xiao Y, Hu X, Jiang L, Zuo WJ, Ma D, Ding J, Zhu X, Zou J, Verschraegen C, Stover DG, Kaklamani V, Wang ZH, Shao ZM. Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial. Cell Res. 2021 Feb;31(2):178-186. doi: 10.1038/s41422-020-0375-9. Epub 2020 Jul 27.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BP102 | Monoclonal antibody | 10 mg/kg | — |
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | — |
| Subject | Capecitabine | Small molecule | 1000 mg/m2 | — |
| Subject | Dalpiciclib | Small molecule | 150 mg | — |
| Subject | Etoposide | Small molecule | 50 mg | — |
| Subject | Everolimus | Small molecule | 10 mg | — |
| Subject | Famitinib | Small molecule | 20 mg | — |
| Subject | Fluzoparib | Small molecule | 150 mg | — |
| Subject | Paclitaxel | Small molecule | 100 mg | — |
| Subject | Pyrotinib | Small molecule | 400 mg | — |
| Subject | Rivoceranib | Small molecule | 250 mg | — |
| Subject | SHR2554 | Small molecule | 300 mg | — |
| Subject | SHR3680 | Unknown | 240 mg | — |
| Subject | mTOR inhibitor with nab-paclitaxel | Unknown | 10 mg | — |